🇺🇸

US SEC Filing Intelligence

· daily

US IPO Pipeline SEC S-1 Filings — May 28, 2026

The IPO pipeline on May 28, 2026, presents a bifurcated landscape: two legitimate growth-oriented filings (Entrata and GridAI) alongside two speculative or distressed situations (Youmi and the Peach State merger). Entrata's S-1 signals a high-profile tech IPO with complex compensation structures tied to majority owner returns, while GridAI's registration for warrant resale reflects a post-reverse-merger transformation into AI infrastructure with zero revenue from its new platform. The Peach State merger (UCB S-4) introduces a traditional banking consolidation with a fixed exchange ratio and regulatory hurdles. Period-over-period comparisons are limited as most filers lack historical financial data, but GridAI's shift from biopharma to AI-data center energy optimization represents a dramatic pivot. Insider activity is absent across filings, but the lack of proceeds to issuing companies (GridAI, Youmi) raises capital structure concerns. The overall sentiment is cautious, with materiality scores uniformly high (8/10) due to the transformative nature of these events.

4 high priority 4 total filings
· daily

Global High-Priority Regulatory Events — May 28, 2026

The 50 filings reviewed today reveal a market dominated by regulatory enforcement actions and capital market transactions, with a notable cluster of government-owned entities facing fines for board composition non-compliance. Revenue growth trends are mixed: Salesforce posted a strong 13.3% YoY revenue increase, while Ashok Leyland’s 13.6% FY26 top-line growth was partially offset by Q4 margin compression. Capital allocation is a key theme, with HP Inc. and Salesforce engaging in aggressive share repurchases, the latter spending $27.4B in the quarter, while Zydus Lifesciences increased its buyback price by 9.6%. The SPAC and de-SPAC landscape shows increased activity, particularly in the energy and nuclear technology sectors, with NewCleo and Hadron Energy nearing public listings. Insider trading activity is sparse, but significant director resignations at Hanmi Financial and Braemar Hotels suggest potential governance shifts. The most critical development is GameStop’s $125/share bid for eBay—a high-risk, transformative M&A move that could reshape e-commerce and collectibles markets if successful.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 28, 2026

The 33 filings reveal a mixed earnings season with revenue growth across most companies but notable margin compression and rising costs. Key themes include strong performance in AI-related and infrastructure services (Marvell, Dycom, EPLUS), while consumer-facing companies (BJ's, Hormel) face margin pressure. Several SPACs and micro-caps show severe cash burn (Aerkomm, IWAC). Insider activity is limited, but capital allocation trends show aggressive buybacks at Salesforce and HealthEquity. Forward-looking data is sparse, but upcoming earnings calls for Deere and Lowe's are key catalysts. Overall, growth is broad but profitability is challenged by restructuring, acquisition costs, and rising SG&A.

33 high priority 33 total filings
· daily

US SEC Trading Suspension Halt Orders — May 28, 2026

All three filings involve Nasdaq deficiency notices received between May 21-22, 2026, highlighting a cluster of compliance failures among small-cap companies. Lulu's Fashion Lounge (LVLU) faces a fundamental equity shortfall with negative stockholders' equity of $(525)K, while CDT Equity and Richtech Robotics both failed to timely file their Form 10-Q for the quarter ended March 31, 2026. No period-over-period comparisons, insider activity, or forward-looking guidance were provided in these filings, limiting quantitative trend analysis. The materiality is highest for LVLU (9/10) due to the existential threat to its listing, while the filing failures for CDT and Richtech are procedural but carry delisting risk if not resolved. The cluster suggests potential systemic issues in compliance or financial reporting among micro-cap issuers.

3 high priority 3 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 28, 2026

The 49 filings from May 28, 2026, reveal a market bifurcated between aggressive corporate actions (M&A, refinancing) and acute financial distress, particularly among small-cap and micro-cap companies. A dominant theme is the wave of refinancing and debt restructuring, with companies like Kinder Morgan, Hexcel, PBF Energy, and Kennametal extending maturities and managing balance sheets, while distressed entities like Nature's Miracle, Celularity, and Allbirds engage in survival-mode settlements and covenant amendments. Distress signals are concentrated in Nasdaq compliance failures, with Lulu's Fashion Lounge, CDT Equity, and Richtech Robotics receiving deficiency notices, and distressed financing (PIPEs, high-interest loans) from ENDRA Life Sciences, Vestand, and Polaryx Therapeutics. On the opportunity side, high-value M&A is a key catalyst, including the $17.6B acquisition of Caesars Entertainment, Autodesk's $3.6B acquisition of MaintainX, and Apogee Enterprises' accretive acquisition of Kalwall. Sector themes point to a capital rotation from distressed small-caps to larger, cash-rich acquirers, with energy infrastructure (Cheniere, Sabine Pass) and AI infrastructure (Boost Run) seeing significant long-term investment commitments. The overall sentiment is cautiously optimistic for large caps with strong balance sheets, but highly bearish for micro-caps facing liquidity crises and potential delisting.

49 high priority 49 total filings
· daily

US Executive Officer Management Changes SEC — May 28, 2026

The 50 filings reveal a mixed landscape of leadership transitions and shareholder sentiment across US equities. Notable trends include several CEO departures (Schmitt Industries, Allogene Therapeutics, Tyson Foods, Clorox, Energy Recovery) and a high volume of board appointments, often bringing operational or regulatory expertise. Insider activity is sparse but includes a significant debt-to-equity conversion by Microvast's CEO. Forward-looking data shows reaffirmed guidance at Tyson Foods and Utz Brands, while Karyopharm's retention program ties equity to clinical milestones. Shareholder dissent is evident at Vir Biotechnology (44.7% withhold for Janet Napolitano), Customers Bancorp (32% against say-on-pay), and Harley-Davidson (climate proposal rejected). Capital allocation trends include dividend declarations at California BanCorp and TFS Financial, with TFSL's MHC waiving dividends. The CECO-Thermon merger received overwhelming approval (99.9%+), signaling strong deal support. Overall, the period shows active governance restructuring with mixed market signals.

50 high priority 50 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 28, 2026

The 50 filings from May 28, 2026, reveal a significant wave of board and C-suite turnover across sectors, with 30+ filings detailing director resignations, CEO successions, and executive appointments. Key themes include a notable shift towards leaner governance structures (e.g., Beeline Holdings, Schmitt Industries), strategic realignments in the C-suite (e.g., Tyson Foods, Allogene Therapeutics, Clorox), and a high volume of annual meeting outcomes showing strong shareholder support for management proposals but pockets of dissent on executive compensation (e.g., Customers Bancorp with 32% against say-on-pay). Period-over-period comparisons were largely absent from these event-driven filings, but forward-looking statements from Tyson Foods (reaffirmed FY2026 guidance) and Utz Brands (reaffirmed outlook) suggest stable near-term expectations. The most critical developments include the sudden CEO departures at Clorox (health reasons) and Energy Recovery (personal reasons), and the simultaneous resignation of three top executives at AIxCrypto Holdings, signaling potential governance instability. Insider activity was limited, but the conversion of a $25M loan by Microvast's CEO is a notable capital allocation event. Overall, the digest points to a period of transition and strategic recalibration, with opportunities in companies executing well-planned successions and risks in those facing abrupt leadership voids.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — May 28, 2026

The 8 filings reveal a mixed M&A landscape with significant sector-specific activity. In energy, TXO Partners and Bimergen Energy are executing asset dispositions and JV formations to reduce debt and fund development, while Tamboran Resources expands acreage in the Beetaloo Basin. The cabinet manufacturing sector sees a transformative merger between MasterBrand and American Woodmark, creating the largest North American player with $90M in expected synergies. Tech-focused deals include Olenox's acquisition of CS Digital Ventures for $30M upfront plus earnouts, and Transglobal's acquisition of Continuum Software via massive dilution. Ashford Hospitality's hotel sale highlights ongoing deleveraging in hospitality. Period comparisons show TXO Partners swinging from a net loss of $21.6M to pro forma net income of $28.5M for FY2025, while Ashford's pro forma net loss improved from $71.1M to $60.7M. Insider activity is sparse, but capital allocation trends favor debt reduction and strategic reinvestment. The overall sentiment is mixed, with positive outlooks for the cabinet merger and Olenox's platform, but risks around dilution, contingent milestones, and early-stage revenues persist.

8 high priority 8 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 28, 2026

The overnight filing period from May 27-28, 2026, reveals a market bifurcated between aggressive capital deployment and financial distress. A dominant theme is the surge in SPAC and de-SPAC activity, with three major business combinations announced or completed: Pasqal (quantum computing) targeting a $2B valuation, NewCleo (nuclear technology) merging with NewHold, and Hadron Energy (micro-reactors) completing its merger with GigCapital7. This is complemented by IBM's $10B quantum computing investment, signaling a strong institutional push into next-gen energy and compute. On the earnings front, consumer-facing companies like Dollar Tree (+7.2% revenue) and Burlington (+14% revenue) show robust top-line growth, but margin pressures are evident across the board, with HP Inc. seeing a 6.4% decline in operating earnings despite 9% revenue growth. The most critical risk signals emanate from deep financial distress at ZRCN Inc. (net loss widening to $1.9B) and Nature's Miracle Holding (debt settlement with 27% reduction but severe cash constraints). Insider activity is notably absent from filings, but capital allocation patterns are stark: Salesforce repurchased $27.4B in stock, while Hyperscale Data raised funds at a dilutive $0.18/share. The overarching theme is a 'haves vs. have-nots' market where strong balance sheets are being used aggressively for M&A and buybacks, while cash-strapped companies resort to dilutive financing and distressed settlements.

30 high priority 20 medium 50 total filings
· daily

NME Blockbuster Approvals — May 27, 2026

This period covers a single FDA approval: Gilead Sciences' BULEVIRTIDE-GMOD (HEPCLUDEX), an NME with Priority Review and Orphan Drug designations for an undisclosed indication. While the approval mix shows no biosimilar or label expansion activity, this NME represents a bullish signal for Gilead, leveraging its established virology franchise. The highest-conviction signal is the approval itself, which strengthens Gilead's pipeline credibility in a high-unmet-need area, though the lack of disclosed peak sales estimates and pricing power limits near-term commercial conviction. Key watch items include payer coverage decisions and the drug's market positioning against existing hepatitis therapies.

1 total filings
· daily

Big Pharma Approvals — May 27, 2026

This period covers a single FDA approval on May 22, 2026: Gilead Sciences Inc’s BULEVIRTIDE-GMOD (HEPCLUDEX), classified as an NME with Priority Review and Orphan Drug designations. The approval is a bullish signal for Gilead, reinforcing its therapeutic area strength in virology and hepatitis B virus (HBV) treatment. No biosimilars or label expansions were approved, making this a narrowly focused event. The key risk is the lack of disclosed peak sales estimates, pricing power, and market position data, which limits full commercial assessment. Investors should watch for Gilead’s launch execution and payer coverage decisions to gauge revenue potential.

1 total filings
· daily

Orphan Drug Approvals — May 27, 2026

The May 27, 2026 orphan drug approval period featured a single approval: Gilead Sciences Inc’s BULEVIRTIDE-GMOD (HEPCLUDEX), an NME granted Priority Review and Orphan Drug designation for an undisclosed indication. While the approval mix shows zero biosimilars or label expansions, the lone NME represents a high-conviction signal given Gilead’s established virology franchise and the regulatory priority assigned. The key bullish signal is the NME’s potential to address an unmet need in a niche orphan population, though the lack of disclosed peak sales estimates, pricing power, and market position data tempers conviction. The key risk is the absence of commercial detail, leaving uncertainty around revenue contribution and competitive dynamics within Gilead’s portfolio.

1 total filings
· daily

New Drug Approvals (Original) — May 27, 2026

During the single-day period of May 27, 2026, the FDA approved one new drug application classified as 'Other' (FALLBACK type), with zero NMEs, biosimilars, or label expansions. The sole approval was Gilead Sciences' BULEVIRTIDE-GMOD (HEPCLUDEX), a Priority Review and Orphan Drug-designated therapy for an undisclosed hepatitis indication. This approval signals a bullish, albeit niche, commercial opportunity for Gilead in a high-unmet-need area, but the lack of disclosed peak sales estimates, pricing power, or market position data limits conviction. The key watch item is Gilead's ability to commercialize this orphan drug in a competitive hepatitis landscape, where pricing and patient access remain critical unknowns.

1 total filings
· daily

New Federal Contractors — May 27, 2026

The single contract in this period, a $104.3M cost-plus-fixed-fee delivery order awarded to Quantech Services Inc. by the GSA, is defense-related and supports the Space and Missile Systems Center (SMC), signaling stable demand for space systems R&D support. The contract is neutral in signal strength (5/10) due to its cost-plus structure, which limits profit upside but reduces execution risk, and a concerning negative outlayed amount (-$5,427) that may indicate funding delays or accounting issues. The small business designation suggests niche positioning, but the full-and-open competition (after exclusion of sources) implies competitive pressure. Key risks include monitoring future outlays to confirm funding flow and the contract's performance through August 2024. No bullish or bearish signals were identified, making this a watch-and-verify situation for investors tracking defense space services exposure.

1 total filings
· daily

Significant Contract Modifications ($10M+) — May 27, 2026

This digest covers a single $104.3M cost-plus-fixed-fee delivery order awarded to Quantech Services Inc. by the General Services Administration (GSA) for Space and Missile Systems Center (SMC) acquisition and financial support. The contract is 100% defense-related, reflecting stable spending in space systems R&D, but the cost-plus structure limits margin upside. The most notable signal is the near-zero outlayed amount (-$5,427), suggesting the contract is in an early stage or faces funding delays, which warrants caution. No bullish or bearish signals are present; the neutral signal strength (5/10) and low materiality (4/10) indicate limited near-term investment impact. Key risk is execution uncertainty tied to funding flow, while the opportunity lies in Quantech's niche positioning in priority defense space programs.

1 total filings
· daily

Contract Deobligations Alert — May 27, 2026

The single contract digest for May 27, 2026, reports a $104.3M deobligation from the General Services Administration (GSA) to Quantech Services Inc., a small business, for Space and Missile Systems Center (SMC) acquisition support. This is a defense-related award with a cost-plus-fixed-fee pricing structure, which limits profit upside but reduces execution risk. The neutral signal (strength 5/10, materiality 4/10) reflects the contract's early-stage funding anomaly—only -$5,427 outlayed—raising questions about cash flow timing or accounting adjustments. The key risk is monitoring future outlays to confirm the contract is fully funded and performing as expected, particularly given the 2024 performance end date and potential CR exposure for space systems spending.

1 total filings
· daily

Contract Option Exercises — May 27, 2026

This digest covers a single $104.3 million contract option exercise period on May 27, 2026, with 100% defense-related spending. The dominant signal is a neutral, cost-plus-fixed-fee delivery order awarded to Quantech Services Inc. by the GSA for Space and Missile Systems Center (SMC) acquisition support. The highest-conviction signal is the contract's tie to stable space systems R&D, a priority defense area, but the near-zero outlayed amount (-$5,427) raises caution about funding flow or accounting anomalies. Key risk is the early-stage funding status, which could indicate execution delays or budget constraints despite the large obligation ceiling.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — May 27, 2026

This digest covers a single $104.3M mega contract awarded to Quantech Services Inc. by the General Services Administration (GSA) for acquisition and financial support to the Space and Missile Systems Center (SMC). The contract is entirely defense-related, reflecting stable demand for space systems R&D support. The highest-conviction signal is neutral given the cost-plus-fixed-fee pricing structure that limits profit upside but reduces risk. A key risk is the near-zero outlayed amount (-$5,427), suggesting minimal initial funding or a potential accounting anomaly that warrants monitoring for cash flow execution.

1 total filings
· daily

High-Value Federal Grants ($5M+) — May 27, 2026

The digest covers a single, defense-related contract from the General Services Administration (GSA) valued at $104.3M, awarded to Quantech Services Inc. for support of the Space and Missile Systems Center (SMC). The cost-plus-fixed-fee pricing structure reduces profit risk but caps margin upside, while the negative outlayed amount (-$5,427) signals either an early-stage funding anomaly or a potential execution risk. This contract aligns with stable DOD space systems spending, but the lack of follow-on outlays and the small business designation warrant cautious monitoring. The overall signal is neutral, with no bullish or bearish catalysts identified from this single award.

1 total filings
· daily

General Federal Contracts — May 27, 2026

This digest covers a single $104.3M cost-plus-fixed-fee delivery order awarded to Quantech Services Inc. by the General Services Administration (GSA) for Space and Missile Systems Center (SMC) acquisition support. The contract is entirely defense-related, reflecting stable demand for space systems R&D support, a priority area under the NDAA. However, the contract's neutral signal strength (5/10) and minimal initial outlay (-$5,427) raise execution and funding flow concerns. The cost-plus structure limits profit upside but reduces risk, while Quantech's small business status suggests niche positioning in a competitive market. Key watch items include monitoring future outlay amounts and option exercises before August 2024.

1 total filings